21:44:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt bolag verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Portföljen inkluderar produkter som innehåller medicinsk cannabis (CBD), med störst inriktning mot kosttillskott och diverse behandlingsvård. Produkterna används exempelvis av patienter som lider av psoriasis, artros och håravfall. Störst verksamhet återfinns inom den nordiska marknaden, där produkterna vidaresäljs under eget varumärke.

Kalender

2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021
2021-09-27 18:38:31

CS MEDICA A/S's ("CS MEDICA" or the "Company") will adjust its financial targets for the fiscal year 2020/2021. The previously communicated financial target of DKK 7 million will be adjusted to approx. DKK 3.6 million. The completion of the process of testing and getting approval by the ethics committee in India was prolonged due to Covid-19, in turn impacting and postponing the finalization of an agreement. The Company is experiencing great interest in the product portfolio and sees no reason to revise future objectives, rather, the Company expects that ongoing in-depth dialogues and already confirmed orders will have a positive impact on results for the coming fiscal year.

CS MEDICA has an ongoing in-depth dialogue with a potential customer with the intention of signing an agreement. Negotiations are ongoing but are delayed due to previous delays in the clinical process in India. The completion of the clinical process of testing and getting approval by the ethics committee in India was prolonged due to Covid-19, in turn affecting the finalization of the agreement. This will impact the previously communicated financial target of DKK 7 million for the fiscal year 2020/2021, which has been adjusted to approx. DKK 3.6 million. The Company expects that ongoing in-depth dialogues and confirmed orders that cannot be booked this fiscal year will instead have a positive impact on results for 2021/2022.

Lone Henriksen comments
"We are experiencing great interest in our product portfolio. However, following the clinical delays in India, we are delayed in negotiations with a potential customer. We expect to finalize the agreement in 2022. However, as a result, we will not achieve our financial target for the fiscal year 2020/2021. Instead, the expected agreement will have a positive impact on the results for 2021/2022. We see no reason to revise our future objectives", comments Lone Henriksen, CEO of CS MEDICA.
 

This is information that CS MEDICA A/S is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company's contact person set out below on September 27th, 2021.